Whole-genome methylation analysis of benign and malignant colorectal tumours

Journal of Pathology

Volumn 229, Issue 5, 2013, Pages 697-704

  Beggs, Andrew D ^a,b   Jones, Angela ^a   El Bahwary, Mona ^d   Abulafi, Muti ^b   Hodgson, Shirley V ^c   Tomlinson, Ian P M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

colorectal cancer; whole genome methylation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DELETED IN COLORECTAL CARCINOMA PROTEIN; GENERAL RECEPTOR FOR PHOSPHOINOSITIDE 1 ASSOCIATED SCAFFOLD PROTEIN; NETRIN; NEUROGENIN 1; PROTEIN; PROTEIN MLH1; ROUNDABOUT RECEPTOR; SLIT PROTEIN; SOMATOMEDIN B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ADENOMA; AGED; AGED, 80 AND OVER; BAYES THEOREM; CARCINOMA; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MEMBRANE PROTEINS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MODELS, GENETIC; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875055696     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4132     Document Type: Article

References (33)

1. Toyota M, Ahuja N, Ohe-Toyota M, et al,. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686.
2. Ogino S, Kawasaki T, Kirkner GJ, et al,. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagnost 2006; 8: 582-588.
3. Nosho K, Irahara N, Shima K, et al,. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3: e3698.
4. Ogino S, Kawasaki T, Kirkner GJ, et al,. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007; 7: 72.
5. Shin SK, Nagasaka T, Jung BH, et al,. Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology 2007; 133: 1849-1857.
6. Barault L, Charon-Barra C, Jooste V, et al,. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-8546.
7. Dahlin AM, Palmqvist R, Henriksson ML, et al,. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16: 1845-1855.
8. Kim JH, Shin SH, Kwon HJ, et al,. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-494.
9. Zlobec I, Bihl M, Foerster A, et al,. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol 2011; 225: 336-343.
10. Yagi K, Akagi K, Hayashi H, et al,. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010; 16: 21-33.
11. Ang PW, Loh M, Liem N, et al,. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010; 10: 227.
12. Hinoue T, Weisenberger DJ, Lange CP, et al,. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-282.
13. Yamauchi M, Morikawa T, Kuchiba A, et al,. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854.
14. Cancer Genome Atlas N,. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
15. Campan M, Weisenberger DJ, Trinh B, et al,. MethyLight. Methods Mol Biol 2009; 507: 325-337.
16. Saeed AI, Bhagabati NK, Braisted JC, et al,. TM4 microarray software suite. Methods Enzymol 2006; 411: 134-193.
17. Subramanian A, Tamayo P, Mootha VK, et al,. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
18. Rigi-Ladiz MA, Kordi-Tamandani DM, Torkamanzehi A,. Analysis of hypermethylation and expression profiles of APC and ATM genes in patients with oral squamous cell carcinoma. Clinical Epigenet 2011; 3: 6.
19. Kim WJ, Vo QN, Shrivastav M, et al,. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 2002; 21: 3864-3871.
20. Roy K, Wang L, Makrigiorgos GM, et al,. Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity. Biochem Biophys Res Commun 2006; 344: 821-826.
21. Weisenberger DJ, Siegmund KD, Campan M, et al,. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
22. Yoo BC, Jeon E, Hong SH, et al,. Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res 2004; 10: 4176-4184.
23. Kim HK, Zhang H, Li H, et al,. Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia 2008; 10: 1411-1420.
24. Zhang J, Yang J, Roy SK, et al,. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003; 100: 9342-9347.
25. Kusaba T, Nakayama T, Yamazumi K, et al,. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 2006; 15: 1445-1451.
26. Allen M, Louise Jones J,. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011; 223: 162-176.
27. White DT, McShea KM, Attar MA, et al,. GRASP and IPCEF promote ARF-to-Rac signaling and cell migration by coordinating the association of ARNO/cytohesin 2 with Dock180. Mol Biol Cell 2010; 21: 562-571.
28. Sherr CJ, Weber JD,. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10: 94-99.
29. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al,. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
30. Ahlquist T, Lind GE, Costa VL, et al,. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 2008; 7: 94.
31. Green C, Schiff D, Khan A, et al,. Effects of riluzole (RZ) and ionizing radiation (IR) in metabotropic glutamate receptor-1 (GRM1)-positive human melanoma. J Clin Oncol 2009; 27: (suppl; abstr 9083).
32. Ciceroni C, Arcella A, Mosillo P, et al,. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology 2008; 55: 568-576.
33. Stein E, Tessier-Lavigne M,. Hierarchical organization of guidance receptors: silencing of netrin attraction by slit through a Robo/DCC receptor complex. Science 2001; 291: 1928-1938.